$NVAX Keep an Eye Out for... MEETS ALL GOALS In Study. The stock has rallied 20.3% in the past year against the industry’s decline of 19.9%. NVAX appears to be a good buy because, In March, the Coalition for Epidemic Preparedness (CEPI) awarded initial funding of $4 million to support Novavax’s efforts to develop a COVID-19 vaccine. Both CEPI and the company are in talks regarding additional funding from CEPI to cover the costs through the phase I.. Novavax, Inc.’s dividends sit at 0% and has a market cap of $605.47 million. In the past 5 years, the stock has fallen 92.83%, making the company something add. Overall, Novavax, Inc. is a stock you want to keep an eye out for. premiumstocknews.com/2020/0...
  • 2
  • 5